Clinical trials: Osteoporosis
Postmenopause, Osteoporosis
Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
The purpose of this study is to evaluate the effect of 20 mg of bazedoxifene in comparison to placebo on bone mineral density after 6 months of therapy in a population of postmenopausal Asian women.
- Trial name
- NCT00384072
- Testing
- bazedoxifene BZA-20
- Where
- 20 sites in China, South Korea and 1 more
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis
Study of Investigational Drug in Osteoporosis (MK-0217-908)
The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis.
- Trial name
- NCT00092053
- Testing
- ibandronate
- Volunteers
- 203 people
- Sponsor
- Organon and Co
Glucocorticoid-induced Osteoporosis
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.
- Trial name
- NCT06588153
- Testing
- Prolia®
- Where
- 16 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
- Trial name
- NCT00676312
- Testing
- PTH134
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Novartis
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Osteoporosis
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
This is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-011 in healthy postmenopausal women.
- Trial name
- NCT00709540
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Postmenopausal Osteoporosis
G56W1 in Women With Postmenopausal Osteoporosis
This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The…
- Trial name
- NCT03720886
- Testing
- rhPTH（1-34） 28.2μg, rhPTH（1-34） 56.5μg, teriparatide acetate(Teribone™)
- Where
- 9 sites in China
- Volunteers
- 148 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Involutional Osteoporosis
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
The present phase II/III, multicenter, randomized, double-blind, parallel group comparative study is designed to evaluate the efficacy and safety of once-monthly oral administration of NE-58095 delayed release (DR) tablets for 12…
- Trial name
- NCT02063854
- Testing
- NE-58095 IR, NE-58095 DR
- Where
- 25 sites in Japan
- Volunteers
- 871 people
- Sponsor
- Takeda
Osteoporosis
Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol
The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis, using a randomized, open-label…
- Trial name
- e-GLORIA (NCT01974167)
- Testing
- Eldecalcitol, Alfacalcidol
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- e-GLORIA trial Protocol Review Committee
Osteoporosis
Osteoporosis Disease Management Demonstration Project (0000-037)
The purpose of this study is to assess the impact of disease management interventions on bone mineral density (BMD) screening rates and osteoporosis treatment rates in women age 65 years or older.
- Trial name
- NCT00139425
- Testing
- Disease Management Assessment
- Volunteers
- 10,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis, Osteopenia
Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
The purpose of this study is to determine whether the intake of a daily dosage of standardized olive extract provides any protection against bone loss.
- Trial name
- NCT00789425
- Testing
- Standardized Extract of Olive Polyphenols
- Where
- Poland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- BioActor
Osteopenia, Osteoporosis
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens.
- Trial name
- NCT01406548
- Testing
- BPS804 20mg/Kg
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteoporosis
Bone Effects of Teriparatide Following Alendronate
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry and architecture.
- Trial name
- NCT00191893
- Testing
- teriparatide
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
To compare change in fractional calcium absorption following administration of MK0217A relative to matching placebo, in postmenopausal women with osteoporosis
- Trial name
- NCT00641771
- Testing
- alendronate sodium (+) cholecalciferol
- Volunteers
- 56 people
- Sponsor
- Organon and Co
Osteoporosis
Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)
To investigate a new incidence and preventive effect of menatetrenone on vertebral fracture in patients with osteoporosis who were randomly assigned to either treatment arm receiving daily dose of calcium supplement as a…
- Trial name
- NCT00165607
- Testing
- MENATETRANONE
- Where
- Japan
- Sponsor
- Eisai Limited
Post Menopausal Osteoporosis
Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis.
- Trial name
- OSTEOAD (NCT07105163)
- Where
- 20 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Procare Health Iberia S.L.
Osteoporosis, Age-Related
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
- Trial name
- NCT02732210
- Where
- 89 sites in United States, Canada
- Volunteers
- 935 people
- Sponsor
- Amgen
Osteoporosis in Post-menopausal Women
Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women
Multicentered, randomized study of safety and efficacy of whole-body vibration (WBV) as add on to standard pharmacological treatment of osteoporosis (alendronate 70 mg/ week or raloxifene 60 mg/day) in post-menopausal women.
- Trial name
- NCT01415050
- Testing
- Whole body vibration
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- X-pert Med GmbH
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Age-Related Bone Loss, Bone Loss, Age Related
Radio-frequency Identification (RFID) Osteoporosis Pilot Study
This examines in-vivo microwave sensing to measure a radio- frequency signal propagating through the wrist and, based on this information, establish a correlation of measured parameters with the integral bone density.
- Trial name
- NCT03385941
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neva Electromagnetics, LLC